Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (141-150 of 539) with videos related to

Pageof 54
Sort By:
British Journal of Haematology|July 9, 2003
Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myelomaPeter Liebisch, Andreas Viardot, Nicole Bassermann, et al.
Haematologica|November 4, 2006
The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failureMarc S Raab, Iris Breitkreutz, Michael Hundemer, et al.
Cancer|April 28, 2011
Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasoneUlrike Klein, Anna Jauch, Thomas Hielscher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2014
Dynamic contrast-enhanced magnetic resonance imaging for assessment of antiangiogenic treatment effects in multiple myelomaMaximilian Merz, Judith Ritsch, Christina Kunz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
Association of antigen-specific T-cell responses with antigen expression and immunoparalysis in multiple myelomaSabrina Fichtner, Dirk Hose, Melanie Engelhardt, et al.
European Journal of Radiology|May 6, 2014
Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell diseaseMaya B Wolf, Fritz Murray, Kerstin Kilk, et al.
European Journal of Haematology|March 11, 2020
First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patientsWolfgang Knauf, Gerrit Dingeldein, Rudolf Schlag, et al.
Journal of Molecular Medicine (Berlin, Germany)|October 18, 2021
COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term viewIvana von Metzler, Julia Campe, Sabine Huenecke, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2019
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and SubgroupsRobert Z Orlowski, Philippe Moreau, Ruben Niesvizky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myelomaJens Hillengass, Klaus Wasser, Stefan Delorme, et al.
Pageof 54

Showing results (141-150 of 539) with videos related to

Sort By:
Pageof 54
British Journal of Haematology|July 9, 2003
Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myelomaPeter Liebisch, Andreas Viardot, Nicole Bassermann, et al.
Haematologica|November 4, 2006
The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failureMarc S Raab, Iris Breitkreutz, Michael Hundemer, et al.
Cancer|April 28, 2011
Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasoneUlrike Klein, Anna Jauch, Thomas Hielscher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2014
Dynamic contrast-enhanced magnetic resonance imaging for assessment of antiangiogenic treatment effects in multiple myelomaMaximilian Merz, Judith Ritsch, Christina Kunz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2015
Association of antigen-specific T-cell responses with antigen expression and immunoparalysis in multiple myelomaSabrina Fichtner, Dirk Hose, Melanie Engelhardt, et al.
European Journal of Radiology|May 6, 2014
Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell diseaseMaya B Wolf, Fritz Murray, Kerstin Kilk, et al.
European Journal of Haematology|March 11, 2020
First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patientsWolfgang Knauf, Gerrit Dingeldein, Rudolf Schlag, et al.
Journal of Molecular Medicine (Berlin, Germany)|October 18, 2021
COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term viewIvana von Metzler, Julia Campe, Sabine Huenecke, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2019
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and SubgroupsRobert Z Orlowski, Philippe Moreau, Ruben Niesvizky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myelomaJens Hillengass, Klaus Wasser, Stefan Delorme, et al.
Pageof 54